Mikhail Blagosklonny is a living legend in the oncology world for his outstanding research contributions. Professor Blagosklonny’s lifetime research has focused on the correlation between the onset of various cancers and age. Mikhail’s objective is to research and figure out the most efficient and affordable treatments for particular cancer strains. The current treatment modalities used to deal with cancer often result in the indiscriminate killing of normal cells. This eminent researcher believes it won’t be long till his research team or others come up with the next-generation of advanced cancer treatments.
Inspiration and Influential Figure
Dr. Mikhail’s significant contributions are an inspiration to countless numbers of young people and he’s equally admired by his academic peers. Today, the existing cancer remedies and solutions are way out of reach to the regular folks, financially. To a significant majority of cancer victims, therapy and cures are a luxury and that is what worries the researcher the most. Dr. Mikhail hopes to live in a future where every cancer patient has easy access to affordable and efficient cancer treatments, at all times.
If there’s one thing that Mikhail Blagosklonny learned by being in the Fastlane of the cancer research realm, it must be the about the power of collaboration. Oncology is a mind-boggling niche with new research findings being released every day. This humungous data makes it nearly impossible for anyone professor or a research team to make breakthroughs in their cancer treatment quests. That’s why Dr. Blagosklonny decided to co-found a unique online peer-to-peer medical research data publishing journal called Oncotarget. Oncotarget went ahead to become one of the biggest research, publishing platforms of our times. Today, Oncotarget contains a wealth of cancer-related research that serves as a vital lifeline for countless graduate students and medical researchers.
In recent times, Dr. Blagosklonny has been experimenting with the potent anti-fungal drug, Rapamycin. Rapamycin, also traded under the generic name, Sirolimus, is used worldwide to reduce organ rejection after transplants. Studies have revealed that Sirolimus also heals lung diseases. The immunosuppressive properties of Sirolimus were first detected by local researchers on the beaches of Easter Island in the 70’s. This drug caught the attention of Dr. Mikhail for the sole reason that it had life-prolonging powers. The researcher envisioned using the anti-aging capabilities of Sirolimus to extend the lives of his cancer patients. It pays that Rapamycin is very easily broken down in the body, hence it doesn’t strain the kidneys during treatments. That is in complete contrast with most of the modern available cancer therapy drugs that end up destroying the kidneys and the liver too.
Research in Progress
Rapamycin is known to discourage the proliferation of cancerous tumors. The drug is highly recommended for patients who’ve just undergone organ transplant operations and have a higher than normal risk of developing tumors. Rapamycin is also used in the both the prevention and treatment of the debilitating congenital disorder, Tuberous Sclerosis Complex (TSC) and Facial angiofibromas. The latter condition manifests as butterfly-shaped rash formations on the face of an affected person. Research is ongoing to determine the exact roles Rapamycin plays in dealing with other severe medical conditions like Alzheimer, Systemic Lupus Erythematosus (SLE) and muscular dystrophy.